Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Golden Meditech's Controlling Shareholder Proposed a Voluntary Conditional Cash Offer at HK$1.25 per share

Freitag, 13.01.2017 15:05 von

PR Newswire

HONG KONG, Jan. 13, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that Mr. Kam Yuen ("Mr. Kam"), the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3"), has proposed a voluntary conditional cash offer to acquire all of the issued shares (other than those already owned or agreed to be acquired by MO3 and its concert parties), all outstanding convertible notes and to cancel all outstanding share options of the Company. MO3 is a special purpose vehicle, which is established by Mr. Kam and Qin Wall Investment Holdings Limited, a company wholly-owned by China Huarong International Holdings Limited, to facilitate the voluntary conditional cash offer.

MO3 intends to maintain the listing status of the ordinary shares of the Company on the Main Board of Hong Kong Stock Exchange and the Taiwan depositary receipts of the Company on the Taiwan Stock Exchange. MO3 undertakes to take appropriate steps within a reasonable period following the close of the voluntary conditional cash offer to ensure that at least 25% of the ordinary shares of the Company will be held by the public.

The offer price of the voluntary conditional cash offer is HK$1.25 per share in cash, representing a premium of approximately 12.61% over the closing price of HK$1.11 per share on 12 January 2017 (the "Last Trading Day") and a premium of approximately 20.19% over the average closing price of HK$1.04 per share for the last 30 trading days prior to and including the Last Trading Day.

The funds required by the voluntary conditional cash offer will be financed from MO3's internal resources as well as the issuance of notes by MO3 to China Minsheng Banking Corp., Ltd. Amasse Capital Limited is acting as the financial adviser to MO3.

Further details of the voluntary conditional cash offer have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company's website as follows: http://www.goldenmeditech.com/eng/ir/announcements.php

About Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801)

Golden Meditech (www.goldenmeditech.com) is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market, the cord blood storage market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/golden-meditechs-controlling-shareholder-proposed-a-voluntary-conditional-cash-offer-at-hk125-per-share-300390777.html

SOURCE Golden Meditech Holdings Limited